Aldena’s JAK-1-selective siRNA; an aerosol mAb for SARS-CoV-2 and more

Aldena Therapeutics Inc., Leo Pharma A/S and collaborators at University of Massachusetts Medical School described in Nature Communications a rationally designed siRNA with selectivity for only JAK-1 and not other JAK family members. In a mouse model of vitiligo, local administration of the JAK-1 siRNA reduced skin infiltration of autoreactive CD8⁺ T cells and prevented epidermal depigmentation.

The technologies in the article are licensed to Aldena for clinical development. According to BioCentury’s BCIQ database, all JAK-1 inhibitors currently in development are small molecules...